Health Care Technology
Company Overview of Schrödinger, LLC
Schrödinger, LLC develops chemical simulation software for use in pharmaceutical and biotechnology research. The company provides products ranging from general molecular modeling programs to a suite of drug design software, including ligand- and structure-based methods. It also provides products in various research areas, including small molecule modeling and simulations, macromolecular modeling and simulations, lead discovery, lead optimization, and visualization and automation. The company’s software allows scientists to accelerate their research and development activities, as well as to make novel discoveries. It serves pharmaceutical and biotech companies, universities, non-profit instit...
101 S.W. Main Street
Portland, OR 97204
Founded in 1990
Key Executives for Schrödinger, LLC
Co-Founder, Chief Operating Officer and Chief Financial Officer
Vice President and General Counsel
Managing Director and Senior Vice President
Senior Vice President of Strategy and Member of the Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Schrödinger, LLC Key Developments
Schrodinger Signs Drug Discovery Collaboration with Sanofi
Apr 7 15
Schrodinger signed a multi-year early drug discovery collaboration with Sanofi. Under the contract, Schrodinger will offer target analysis and validation to lead identification and lead optimisation for around ten drug discovery programmes. Schrodinger is to receive up to USD 120 million, which includes preclinical milestones. A new enterprise informatics system will also facilitate real-time collaboration between computational designers and medicinal chemists and will serve as the communications and project management platform for researchers across both firms.
Sanofi Signs $120 million Collaboration Agreement with Schrodinger
Apr 2 15
Sanofi announced it has entered into a collaboration agreement with Schrodinger. Under the agreement, Schrodinger will provide comprehensive computational drug design support for as many as ten drug discovery programs. In return, Sanofi will pay up to $120 million, including pre-clinical milestones.
Schrödinger Inc. and Professor Mark E. Thompson Announce Research Collaboration to Enable Computer-Aided Design of Organic Semiconductor Materials
Jun 27 13
Schrödinger Inc. and Dr. Mark E. Thompson, Professor of Chemistry at the University of Southern California, announced their joint research collaboration to advance the development and design of organic semiconductor materials through use of atomic-scale simulations. Organic semiconductors are a class of materials that have a wide range of electronic device applications, including organic solar cells and detectors, organic light-emitting diodes (OLEDs), and thin-film transistors. Evaluating expansive chemical space to identify good synthetic targets for organic semiconductors is a challenge that limits the rate of new organic materials development. Schrödinger has previously developed software tools for the discovery of new drug candidates through a method known as virtual screening, which involves the use of high-throughput simulation techniques to predict the candidate systems' chemical properties followed by ranking to identify the most promising lead systems. One of the focuses of this collaboration is to leverage these virtual screening methods for the discovery of novel organic semiconductor materials. Schrödinger's Materials Science Suite 1.0 is available now and provides atomic-scale simulation capabilities for chemical systems used in a wide range of technological applications, including optoelectronics, functional additives, engineered catalysts, and reactive precursors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|